During the biotech industry's extended market bull run there has been a notable resurgence of interest in advanced gene and cell therapies. In fact, the Washington-based Alliance for Regenerative Medicine (ARM), an international advocacy organization representing the regenerative medicine and advanced therapies community, hailed 2014 as a breakout year for the sector during its annual state-of-the-industry briefing presented at the Biotech Showcase meeting in January. Read More
The brutal capital markets in August didn't deter biotech companies taking off from the IPO runway, with five successfully completing their offerings in the month, raising almost $400 million among them. The financings are a reflection of strong IPO activity in general during the second quarter. Read More
